Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    July 2018
  1. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed     Text format    


  2. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed     Text format    


    June 2018
  3. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Text format     Abstract available


    May 2018
  4. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Text format     Abstract available


  5. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Text format     Abstract available


  6. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed     Text format    


  7. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Text format     Abstract available


  8. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Text format     Abstract available


    April 2018
  9. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Text format     Abstract available


  10. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Text format     Abstract available


    February 2018
  11. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Text format     Abstract available


  12. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Text format     Abstract available


  13. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Text format     Abstract available


    January 2018
  14. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Text format     Abstract available


  15. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Text format     Abstract available


    December 2017
  16. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Text format     Abstract available


  17. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Text format     Abstract available


  18. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Text format     Abstract available


    November 2017
  19. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Text format     Abstract available


  20. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Text format     Abstract available


    October 2017
  21. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Text format     Abstract available


  22. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Text format     Abstract available


  23. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Text format     Abstract available


  24. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed     Text format    


    September 2017
  25. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Text format     Abstract available


  26. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Text format     Abstract available


  27. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Text format     Abstract available


  28. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Text format     Abstract available


  29. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Text format     Abstract available


    August 2017
  30. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Text format     Abstract available


  31. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Text format     Abstract available


  32. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Text format     Abstract available


  33. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Text format     Abstract available


  34. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Text format     Abstract available


    July 2017
  35. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Text format     Abstract available


    June 2017
  36. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Text format     Abstract available


    May 2017
  37. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Text format     Abstract available


  38. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed     Text format    


  39. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Text format     Abstract available


  40. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Text format     Abstract available


  41. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Text format     Abstract available


    April 2017
  42. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Text format     Abstract available


  43. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Text format     Abstract available


  44. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Text format     Abstract available


    March 2017
  45. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Text format     Abstract available


  46. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed     Text format    


  47. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Text format     Abstract available


    February 2017
  48. ZHENG YX, Zhou PC, Zhou RR, Fan XG, et al
    The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Feb 24. doi: 10.1097/MEG.0000000000000867.
    PubMed     Text format     Abstract available


  49. TAVARES RC, Feldner AC, Pinho JR, Uehara SN, et al
    Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2017 Feb 23. doi: 10.1097/MEG.0000000000000866.
    PubMed     Text format     Abstract available


  50. RONCERO C, Littlewood R, Vega P, Martinez-Raga J, et al
    Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.
    Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000855.
    PubMed     Text format     Abstract available


  51. SU F, Beste LA, Green PK, Berry K, et al
    Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Eur J Gastroenterol Hepatol. 2017 Feb 13. doi: 10.1097/MEG.0000000000000858.
    PubMed     Text format     Abstract available


  52. NORTH CS, Pollio DE, Sims OT, Jain MK, et al
    An effectiveness study of group psychoeducation for hepatitis C patients in community clinics.
    Eur J Gastroenterol Hepatol. 2017 Feb 13. doi: 10.1097/MEG.0000000000000860.
    PubMed     Text format     Abstract available


  53. SILVA MJ, Pereira C, Loureiro R, Balsa C, et al
    Hepatitis C in a Mobile Low-Threshold Methadone Program.
    Eur J Gastroenterol Hepatol. 2017 Feb 1. doi: 10.1097/MEG.0000000000000843.
    PubMed     Text format     Abstract available


  54. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Text format     Abstract available


    January 2017
  55. THONNES S, Friedel H, Frohlich H
    The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data.
    Eur J Gastroenterol Hepatol. 2017 Jan 12. doi: 10.1097/MEG.0000000000000819.
    PubMed     Text format     Abstract available


    December 2016
  56. TOSON EA, Shiha GE, El-Mezayen HA, Samir W, et al
    Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  57. LAPI F, Capogrosso Sansone A, Mantarro S, Simonetti M, et al
    Hepatitis C virus infection: opportunities for an earlier detection in primary care.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  58. MCEWAN P, Selvapatt N, Brown A, Thursz M, et al
    A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  59. TURNER BJ, Liang Y, Singal A
    FIB-4 and imaging for measuring fibrosis in hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  60. NORDSTROM EM, Keniston A, Baouchi F, Martinez-Camacho A, et al
    Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  61. WIJARNPREECHA K, Thongprayoon C, Ungprasert P
    Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  62. BURLONE ME, Pedrinelli AR, Giarda P, Minisini R, et al
    Influence of age on sex-related differences among patients with hepatitis C.
    Eur J Gastroenterol Hepatol. 2016;28:1100-1.
    PubMed     Text format    


    August 2016
  63. SCHULZ M, Beha D, Plehm K, Zollner C, et al
    High prevalence of anti-hepatitis E virus antibodies in outpatients with chronic liver disease in a university medical center in Germany.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  64. LEWIS H, Kunkel J, Axten D, Dalton J, et al
    Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  65. BERT F, Rindermann A, Abdelfattah MA, Stahmeyer JT, et al
    High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  66. MANCEBO M, Real LM, Mira JA, Recio E, et al
    Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  67. PIERUCKA M, Stalke P, Zagozdzon P, Smiatacz T, et al
    The prevalence and co-occurrence of hematological complications at the time of diagnosis of chronic hepatitis C in Poland: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  68. MARCELLIN F, Fournier I, Carrieri MP, Poizot-Martin I, et al
    From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).
    Eur J Gastroenterol Hepatol. 2016;28:733-4.
    PubMed     Text format    


    May 2016
  69. MARCELLIN F, Protopopescu C, Poizot-Martin I, Miailhes P, et al
    Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  70. TOSON EA, Shiha GE, El-Mezayen HA, El-Sharkawy AM, et al
    Diagnostic performance of T lymphocyte subpopulations in assessment of liver fibrosis stages in hepatitis C virus patients: simple noninvasive score.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  71. ABDEL-RAZIK A, Elhelaly R, Elzehery R, El-Diasty A, et al
    Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Eur J Gastroenterol Hepatol. 2016;28:599-605.
    PubMed     Text format     Abstract available


    April 2016
  72. ZEUZEM S, Mantry P, Soriano V, Buynak RJ, et al
    Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  73. KARAGOZ E, Tanoglu A, Ulcay A, Erdem H, et al
    Mean platelet volume and red cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  74. LISON H, Garioud A, Halfon P, Jambon S, et al
    Cytolytic hepatitis related to simeprevir overdose in a patient with cirrhosis and HIV-HCV genotype 1 coinfection.
    Eur J Gastroenterol Hepatol. 2016;28:486-7.
    PubMed     Text format    


    March 2016
  75. GULATI R, Nawaz M, Pyrsopoulos NT
    Comparative analysis of online patient education material pertaining to hepatitis and its complications.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  76. DINTSIOS CM
    Re: Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? (Eur J Gastroenterol Hepatol 2015, 27:1063-1068).
    Eur J Gastroenterol Hepatol. 2016;28:362.
    PubMed     Text format    


    February 2016
  77. WASZCZUK E, Waszczuk KM, Mulak A, Paradowski L, et al
    Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  78. HELAL GK, Gad MA, Abd-Ellah MF, Mahgoup EM, et al
    Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  79. CARVALHANA SC, Leitao J, Alves AC, Bourbon M, et al
    Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  80. CORSI DJ, Karges W, Thavorn K, Crawley AM, et al
    Influence of female sex on hepatitis C virus infection progression and treatment outcomes.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  81. OZDEN HT
    Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  82. WANG H, Innes H, Hutchinson SJ, Goldberg DJ, et al
    The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large 'real world' cohort.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  83. SAEZ-ROYUELA F, Linares P, Cervera LA, Almohalla C, et al
    Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  84. ABDEL-RAZIK A, Mousa N, Abdel-Aziz M, Elhelaly R, et al
    Elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  85. DETERDING K, Gruner N, Buggisch P, Galle PR, et al
    Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  86. MARTIN DJ, Weideman R, Crook T, Brown G, et al
    Relationship of hepatic fibrosis, cirrhosis, and mortality with cholecystectomy in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  87. FEILLANT M, Jezequel C, Lison H, Delluc A, et al
    Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  88. MCEWAN P, Bennett H, Ward T, Webster S, et al
    The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  89. KOHLA MA, El-Said H, El-Fert A, Ehsan N, et al
    Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  90. NICOLINI LA, Menzaghi B, Ricci E, Martinelli C, et al
    Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  91. EMINLER AT, Ayyildiz T, Irak K, Kyc M, et al
    AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  92. SERRES L, Vasseur P, Tougeron D, Gand E, et al
    Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  93. TRIPPOLI S, Fadda V, Maratea D, Messori A, et al
    Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2015;27:983-4.
    PubMed     Text format    


    July 2015
  94. KHEDR MA, E Behairy B, Hussein ME, Marei AM, et al
    Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  95. VERGARA M, Bejarano G, Dalmau B, Gil M, et al
    Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2015;27:826-833.
    PubMed     Text format     Abstract available


    June 2015
  96. PACOU M, Basso F, Gore C, Hass B, et al
    Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter?
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  97. OZARAS R, Tahan V, Ozbay G, Ozturk R, et al
    Hepatic apoptotic markers are not predictors for the virological response to interferon-based therapy in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    February 2015
  98. KAYADIBI H, Sertoglu E, Uyanik M
    Which diagnostic tool for the prediction of intermediate liver fibrosis stages?
    Eur J Gastroenterol Hepatol. 2015;27:182.
    PubMed     Text format    


    January 2015
  99. MORIHARA D, Watanabe H, Takata K, Iwashita H, et al
    Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
    Eur J Gastroenterol Hepatol. 2015;27:55-64.
    PubMed     Text format     Abstract available


    July 2014
  100. HEIDRICH B, Cetindere A, Beyaz M, Stahmeyer JT, et al
    High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting.
    Eur J Gastroenterol Hepatol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: